索非那新联合坦索罗辛治疗前列腺增生伴膀胱过度活动症的有效性Meta分析  

The efficacy of combined therapyof solifenacin plus tamsulosin for prostatic hyperplasia and overactive bladder:a Meta-analysis

作　　者：苏鹏超 赵继懋[1] 宋健[1] 丰琅[1] 张道新[1] 

机构地区：[1]首都医科大学附属北京友谊医院泌尿外科,北京100050

出　　处：《现代泌尿外科杂志》2015年第11期794-797,共4页Journal of Modern Urology

摘　　要：目的比较索非那新(SOL)联合坦索罗辛(TAM)与单用TAM治疗前列腺增生合并膀胱过度活动症的有效性及安全性。方法检索国内外SOL+TAM与单用TAM治疗前列腺增生合并膀胱过度活动症患者疗效,按预定的纳入标准筛选出6篇研究进行质量评价,提取数据进行Mete分析。结果 SOL+TAM显著降低前列腺症状评分-2.18,95%CI(-3.80,-0.56),提高最大尿流率0.8,95%CI(0.04,1.56),降低膀胱过度活动症评分-3.05,95%CI(-5.11,-0.98),尿潴留的发生率为1.3%。结论现有研究证实了SOL+TAM比单用TAM能有效地缓解前列腺增生下尿路症状和膀胱过度活动症状,而其发生尿潴留的绝对风险偏低。SOL+TAM值得推荐前列腺增生合并膀胱过度活动症患者的临床用药。Objective To investigate the efficacy and safety of solifenaein （SOL） plus tamsulosin （TAM） in the treat- ment of prostatic hyperplasia complicated with overactive bladder. Methods Clinical trails on SOL ＋ TAM and TAM alone to treat prostatic hyperplasia complicated with overactive bladder were searched. Altogether 6 trails were included. Data were then analyzed, including changes in International Prostate Symptom Score （IPSS）, IPSS-QOL （quality of life）, maximal urinary flow rate （Qmax）, and Overactive Bladder Symptom Scores （OABSS）. Results Combined therapy could significantly reduce IPSS -2.18, 95% CI （-3.80,-0.56）, reduce OABSS -3.05, 95%o CI （-5.11,-0.98）, and improve the maximal urinary flow rate 0.8, 95% CI （0.04, 1.56）. The incidence of urinary retention was 1.3% . Conclusions The combined treatment of solifenacin plus tamsulosin significantly reduces IPSS and OABSS. This approach is safe with a minimal risk of acute urinary retention. It is worth wide clinical application.

关 键 词：索非那新 坦索罗辛 前列腺增生 膀胱过度活动症 META分析 

分 类 号：R697.32[医药卫生—泌尿科学]